Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)

Trial Profile

Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elasomeran (Primary) ; Tozinameran (Primary) ; Ocrelizumab
  • Indications COVID 2019 infections
  • Focus Pharmacodynamics
  • Acronyms VIOLA
  • Most Recent Events

    • 07 Nov 2023 Status changed from active, no longer recruiting to completed.
    • 28 Oct 2022 Results reporting antibody and cellular responses to mRNA COVID-19 vaccines over 24 weeks presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 04 Apr 2022 Planned End Date changed from 14 Oct 2022 to 14 Oct 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top